Monthly subscriptions are coming soon.Explore 15% savings
AccountBag
IPCJ-PW-5MG-5MGResearch material
Ipamorelin/CJC-1295
Defined materials. Documented research.Product record

Conceptual scientific graphic. Refer to the product and lot record for identity and analytical results.

Find COA / lot documentation

Ipamorelin/CJC-1295 (w/o DAC)

$65.00

Ipamorelin / CJC-1295 (without DAC) is a research peptide blend supplied for controlled laboratory studies. Researchers use this combination in structured research focused on peptide signaling and interaction behavior.

  • Combination of Ipamorelin and CJC-1295 without a Drug Affinity Complex
  • Used in laboratory research focused on peptide signaling and interaction models
  • Suitable for controlled and repeatable research workflows

Monthly plan $55.25/ month

Monthly subscriptions are coming soon. See plan details.

In stock

SKU: IPCJ-PW-5MG-5MG Categories: , , , , , Tag: Brand:

Description

Ipamorelin / CJC-1295 (Without DAC) Research Peptide Blend

Ipamorelin / CJC-1295 (without DAC) is a research peptide blend supplied for controlled laboratory investigation. Researchers study this combination in structured research focused on peptide signaling, receptor interaction models, and sequence specific behavior within experimental systems. The absence of a Drug Affinity Complex allows laboratories to examine peptide activity without extended binding modifications.

Because this blend combines two distinct peptides, researchers use it to explore how paired peptide signaling behaves under controlled research conditions. The non-DAC form of CJC-1295 allows scientists to study shorter acting peptide dynamics and interaction patterns within experimental models. As a result, laboratories can generate clear and repeatable data while maintaining precise control over experimental variables.

In laboratory settings, scientists handle Ipamorelin / CJC-1295 (without DAC) using standard peptide preparation and safety procedures. The peptide format supports accurate measurement and controlled application during experiments. Therefore, research teams can maintain stable testing conditions and focus on observation, documentation, and data analysis.

Researchers value this peptide blend for its defined structure and compatibility with structured research workflows. Its consistent composition helps reduce variation during experimentation and supports comparison across studies involving single and combined peptide sequences. In addition, the non-DAC formulation makes it suitable for research projects that focus on peptide behavior without extended binding effects.

Ongoing scientific research continues to include Ipamorelin / CJC-1295 (without DAC) in peptide focused laboratory studies. Its defined composition, predictable handling characteristics, and suitability for controlled research models make it a useful tool for advanced experimental work.

Important Notice

Ipamorelin / CJC-1295 (without DAC) is provided strictly for research use only. This product is not intended for human or animal use, clinical applications, diagnostic procedures, or consumption of any kind. All research must be conducted by qualified professionals in appropriate laboratory environments and in compliance with applicable regulations and guidelines.

Reviews

There are no reviews yet.

Be the first to review “Ipamorelin/CJC-1295 (w/o DAC)”

Your email address will not be published. Required fields are marked *

What are Ipamorelin and CJC-1295 (without DAC)?

Ipamorelin is a synthetic peptide that acts on the ghrelin receptor (growth hormone secretagogue receptor) to promote growth hormone secretagogue signaling, while CJC-1295 (without DAC), also known as Modified GRF (1-29), is a growth hormone-releasing hormone analogue that targets the GHRH receptor. Combined, they engage distinct pathways to investigate coordinated activation of growth hormone axis signaling.

How does Ipamorelin work at the receptor level?

Ipamorelin activates the ghrelin receptor (GHS-R1a), triggering intracellular signaling cascades, including calcium mobilization, that are associated with the stimulation of growth hormone release from pituitary cells.

How does CJC-1295 (without DAC) function mechanistically?

CJC-1295 (without DAC) binds to growth hormone-releasing hormone (GHRH) receptors on somatotroph cells in the pituitary, activating cAMP/PKA intracellular signaling pathways that support growth hormone axis release mechanisms.

Why are Ipamorelin and CJC-1295 (without DAC) studied together?

In experimental research, these peptides are studied together because they act on separate but complementary signaling networks — Ipamorelin on the ghrelin receptor and CJC-1295 (without DAC) on the GHRH receptor — allowing simultaneous investigation of multiple mechanisms involved in growth hormone axis regulation.

What is known about the half-life of CJC-1295 (without DAC)?

Compared with CJC-1295 with DAC, which binds to serum proteins and has an extended presence, CJC-1295 (without DAC) has a relatively short half-life, generally on the order of tens of minutes to about an hour in experimental systems, enabling more pulsatile signaling.

What types of biological responses are associated with Ipamorelin and CJC-1295 (without DAC) in research?

Studies indicate that Ipamorelin and CJC-1295 (without DAC) can modulate endogenous growth hormone axis activity through separate signaling pathways. CJC-1295 elicits more prolonged activation of growth hormone release mechanisms, while Ipamorelin produces rapid but short-lived signaling responses, allowing researchers to analyze patterns of hormone secretion and downstream intracellular effects.

Related products